Depression & Addiction

Understanding depression and how it connects to substance use

Major depressive disorder (MDD) and persistent depressive disorder (dysthymia) are far more than prolonged sadness. According to the DSM-5, a diagnosis of MDD requires five or more symptoms lasting at least two consecutive weeks, including depressed mood or loss of interest (anhedonia), changes in sleep and appetite, fatigue, difficulty concentrating, feelings of worthlessness, and, in the most severe presentations, recurrent thoughts of death or suicidal ideation. Dysthymia involves a lower-level but chronically depressed mood persisting for two or more years.

Depression drains the brain of dopamine, serotonin, and norepinephrine, the very neurotransmitters that regulate energy, motivation, and pleasure. That deficit is what makes alcohol, opioids, cannabis, and stimulants so appealing as short-term relief: they temporarily flood the reward system. The relief lasts hours. The neurochemical debt it creates lasts far longer, and repeated use actually downregulates the brain's natural capacity to produce those same neurotransmitters, making depression harder to treat without addressing the substance use at the same time.

According to SAMHSA's 2022 National Survey on Drug Use and Health, an estimated 21.5 million U.S. adults experienced co-occurring mental illness and substance use disorder in the prior year. Major depressive disorder consistently ranks among the most common mental health diagnoses alongside alcohol use disorder and opioid use disorder. People are not weak or broken for developing both. The biology makes this combination predictable.

The self-medication cycle and why it hardens over time

The self-medication hypothesis, first articulated by psychiatrist Edward Khantzian, proposes that people choose specific substances based on the psychological relief they provide. Someone with anhedonic, low-energy depression may reach for stimulants or alcohol to feel alive; someone with agitated, anxious depression may reach for alcohol, cannabis, or opioids to quiet the inner noise. The substance choice is rarely random.

What begins as relief quickly becomes compulsion. As tolerance builds, the original dose no longer produces the same effect, and larger amounts are needed to stay even. Meanwhile, withdrawal from alcohol and opioids in particular produces a pronounced depressive syndrome that can be clinically indistinguishable from major depression, making it nearly impossible for someone in early abstinence to know whether the depression was always there or is a product of withdrawal. This is one of the most clinically important reasons integrated assessment matters: both conditions need to be on the table from day one.

Research published in JAMA Psychiatry and consistent with NIMH guidance shows that people with MDD who also have a substance use disorder experience more severe depressive episodes, more hospitalizations, higher relapse rates, and worse functional outcomes than people with depression alone. Integrated treatment substantially closes that gap.

Why integrated treatment outperforms sequential care

For decades, the standard of care was sequential: get sober first, then address the mental health. That model failed a generation of patients, because the untreated depression kept driving them back to substances, and the untreated addiction kept overwhelming every gain in depression treatment.

Today, both NIMH and SAMHSA identify integrated, simultaneous treatment as the clinical standard for co-occurring disorders. Treating both at the same time, under one coordinated plan, by one clinical team, produces demonstrably better outcomes: lower relapse rates, greater completion of treatment, improved quality of life, and better long-term functioning. At The Archangel Centers, that principle is how every dual-diagnosis client is treated from the first day.

Integration also means no referral handoffs, no contradictory instructions from two separate providers who have never spoken, and no gaps for the client to fall through. The same psychiatrist who manages antidepressant dosing knows exactly what the therapist is working on in CBT. The same therapist addressing negative thought patterns knows the status of the medication plan. Every clinical decision is coordinated.

Therapies and clinical tools used in treatment

The Archangel Centers uses an evidence-based, multimodal treatment approach in which each modality addresses a distinct mechanism of the co-occurring condition.

• Cognitive behavioral therapy (CBT): restructures the negative automatic thoughts, cognitive distortions, and behavioral withdrawal patterns that maintain both depression and substance use
• Dialectical behavior therapy (DBT): builds emotional regulation, distress tolerance, and interpersonal effectiveness skills that reduce the emotional drivers of relapse
• Behavioral activation: interrupts the depression-driven cycle of withdrawal from activities by scheduling and reinforcing engagement with meaningful, rewarding behaviors
• Motivational interviewing (MI): resolves ambivalence about recovery and builds intrinsic motivation for change in clients who are not yet fully ready
• Trauma-informed care: addresses co-occurring trauma that frequently underlies both depression and substance use, with EMDR available in individual therapy when clinically appropriate
• Medication-assisted treatment (MAT): Suboxone, Vivitrol, and Sublocade are available through our on-site medical provider for eligible clients with opioid use disorder
• Psychiatric medication management: our on-site provider evaluates, initiates, and titrates antidepressant and other psychiatric medications, with careful attention to interactions with MAT and abuse potential
• PHQ-9 monitoring: standardized depression severity tracking at intake and throughout treatment, allowing medication and therapy adjustments before a decline becomes a crisis
• Safety planning: completed on admission day and revisited throughout treatment, addressing warning signs, coping strategies, support contacts, and crisis resources
• Family programming: family therapy and education available at both locations under signed release, led by co-founder Lauren Sorrentino

What the three stages of treatment look like day to day

Stage one is assessment and stabilization. On admission day, clients complete a comprehensive clinical assessment with their primary therapist, an intake with our on-site medical provider, a PHQ-9 depression screen, and a safety plan. The assessment battery includes ASAM criteria, LOCUS mental health acuity scoring, GAD-7 anxiety screening, and the Columbia Suicide Severity Rating Scale. For clients with acute withdrawal or psychiatric symptoms beyond outpatient scope, we coordinate with partner facilities before programming begins.

Stage two is skill building. Over the following weeks, clients engage in CBT restructuring sessions, behavioral activation planning, DBT skill groups, relapse prevention work, and trauma-informed group programming. The medical provider monitors sleep, appetite, energy, and mood at regular intervals and adjusts medication as symptoms evolve. PHQ-9 scores provide an objective trend line to track whether the depression is responding.

Stage three is integration and discharge planning. Work shifts toward applying skills in the real world, extending behavioral activation outside sessions, and building a relapse-prevention plan that covers both depressive and substance-use recurrence. The team coordinates aftercare, connecting clients to outpatient continuing care, alumni programming, and outside providers before discharge from any higher level of care.

Outpatient levels of care: Partial Care, IOP, and outpatient

Co-occurring depression and addiction frequently require intensive early stabilization because two clinical conditions are being addressed at once. Partial Hospitalization (Partial Care) at our Tinton Falls, New Jersey clinic runs six days per week, Monday through Saturday, providing full-day structure and close psychiatric oversight. At our Charlotte, North Carolina location, PHP runs five days per week, Monday through Friday. Both are designed for adults with significant functional impairment, including disrupted sleep, inability to work or care for dependents, or active safety concerns that stop short of requiring inpatient hospitalization.

Intensive Outpatient (IOP) is available at both locations on a schedule of three or five days per week, with three-hour sessions. IOP is the most work-compatible level of care and serves clients who are stepping down from Partial Care or who present initially with moderate symptoms. Standard outpatient continuing care follows, with reduced clinical contact and ongoing individual therapy, periodic medical follow-up, and group access.

Virtual treatment is available to New Jersey residents, allowing clients in that state to receive IOP or outpatient care by secure video when commuting to Tinton Falls is not feasible. The Archangel Centers does not provide medical detox or inpatient residential treatment; when a client needs that level of care first, our admissions team coordinates placement and brings them into our outpatient program once they are medically stable.

Insurance coverage and cost of treatment

The Mental Health Parity and Addiction Equity Act (MHPAEA) requires most insurance plans to cover mental health and substance use disorder treatment at the same level as medical or surgical benefits. In practice, this means most major commercial plans cover medically necessary outpatient dual-diagnosis treatment for depression and addiction.

The Archangel Centers is in-network with Aetna, Cigna, BlueCross BlueShield, United Healthcare, Horizon BCBS, AmeriHealth NJ, Humana, and Tricare. Our admissions team verifies benefits for free before any commitment, typically within the same call, so clients know their real out-of-pocket cost before they decide. Sliding scale and payment plan options exist for clients without adequate coverage. Medicaid coverage and eligibility for each location can be confirmed during the free verification call.

Cost should not be the reason anyone delays treatment. The long-term financial, occupational, and health consequences of untreated co-occurring depression and addiction consistently exceed the cost of treatment by a significant margin. Our team will work to find an affordable path.

Getting started: the admissions process

Admissions at The Archangel Centers is confidential, available 24 hours a day, and requires no prior referral. Calling (888) 464-2144 connects you or your loved one directly to an admissions specialist who can verify insurance, discuss levels of care, and in most cases offer same-week placement. The clinical team determines the appropriate level of care during an initial assessment, not before it, so you do not need to arrive with a firm plan in mind.

For families and loved ones calling on behalf of someone struggling, our team can discuss options, explain the intake process, and help with the conversation of asking someone to accept help. No one has to navigate this alone.